IOXAGLATE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H20I6N5O8.Na
Molecular Weight	1290.8609
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C([O-])=O)=C(I)C(C(=O)NCCO)=C2I)=C1I

InChI

InChIKey=MBVDCEVFLAONHO-UHFFFAOYSA-M

InChI=1S/C24H21I6N5O8.Na/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43;/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H20I6N5O8
Molecular Weight	1267.8711
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018905s024lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6999377 | https://www.ncbi.nlm.nih.gov/pubmed/21414657 | https://www.drugs.com/pro/hexabrix.html | https://www.ncbi.nlm.nih.gov/pubmed/2022451 | https://www.ncbi.nlm.nih.gov/pubmed/11271894

Ioxaglate Sodium Meglumine (trade name Hexabrix) is a new low osmolality ionic contrast agent, that used as a diagnostic radiopaque medium. Following intravascular injection, Ioxaglate Sodium Meglumine is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine. The joint spaces as well as the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied. The usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). The doses may be repeated as necessary Patients may have clinically insignificant ECG changes during the procedure. The following adverse effects have occurred in conjunction with the administration of iodinated intravascular contrast agents for this procedure: hypotension, shock, anginal pain, myocardial infarction, cardiac arrhythmias (bradycardia, ventricular tachycardia, ventricular fibrillation) and cardiac arrest.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thrombin 21 Target ID: CHEMBL204 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12871500	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Kidney failure 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	Diagnostic	Approved 8583	HEXABRIX Approved Use INDICATIONS AND USAGE. Launch Date 1986
Brain disease 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	Diagnostic	Approved 8583	HEXABRIX Approved Use INDICATIONS AND USAGE. HEXABRIX is indicated for use in pediatric angiocardiography, selective coronary arteriography with or without left ventriculography, peripheral arteriography, aortography, selective visceral arteriography, cerebral angiography, intra-arterial digital subtraction angiography, intravenous digital subtraction angiography, peripheral venography (phlebography), excretory urography, contrast enhancement of computed tomographic head imaging and body imaging, arthrography and hysterosalpingography. Launch Date 1986
Coronary artery disease 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	Diagnostic	Approved 8583	HEXABRIX Approved Use INDICATIONS AND USAGE. HEXABRIX is indicated for use in pediatric angiocardiography, selective coronary arteriography with or without left ventriculography, peripheral arteriography, aortography, selective visceral arteriography, cerebral angiography, intra-arterial digital subtraction angiography, intravenous digital subtraction angiography, peripheral venography (phlebography), excretory urography, contrast enhancement of computed tomographic head imaging and body imaging, arthrography and hysterosalpingography. Launch Date 1986
Coronary artery disease 48 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018905s024lbl.pdf	Diagnostic	Approved 8583	Hexabrix Approved Use Coronary Angiography Launch Date 1985
Vascular cerebral disorders 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018905s024lbl.pdf	Diagnostic	Approved 8583	Hexabrix Approved Use Cerebral angiography Launch Date 1985
Vein disease 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018905s024lbl.pdf	Diagnostic	Approved 8583	Hexabrix Approved Use Peripheral venography (phlebography) Launch Date 1985
Joint disorder 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018905s024lbl.pdf	Diagnostic	Approved 8583	Hexabrix Approved Use arthrography Launch Date 1985
Urinary tract disorders 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018905s024lbl.pdf	Diagnostic	Approved 8583	Hexabrix Approved Use excretory urography Launch Date 1985

C_max

Value	Dose	Co-administered	Analyte	Population
2100 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	26.663 g single, intravenous dose: 26.663 g route of administration: Intravenous experiment type: SINGLE co-administered:		IOXAGLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
92 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	26.663 g single, intravenous dose: 26.663 g route of administration: Intravenous experiment type: SINGLE co-administered:		IOXAGLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
101 mL single, intraarterial Recommended Dose: 101 mL Route: intraarterial Route: single Dose: 101 mL Sources: https://pubmed.ncbi.nlm.nih.gov/1552109	unhealthy, 59+/-11 Health Status: unhealthy Age Group: 59+/-11 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1552109	Other AEs: Chest pain, Nausea... Other AEs: Chest pain (grade 1-2, 4.4%) Nausea (grade 1-2, 6.4%) Vomiting (grade 1-2, 1.6%) Allergic skin reaction (grade 1-2, 5.2%) Bronchospasm (grade 3, 0.8%) Warmth (grade 1-2, 4.4%) Bad taste (grade 1-2, 0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/1552109
194.8 mL single, intravenous Recommended Dose: 194.8 mL Route: intravenous Route: single Dose: 194.8 mL Sources: https://pubmed.ncbi.nlm.nih.gov/16949481	unhealthy, 68.7+/-7.5 Health Status: unhealthy Age Group: 68.7+/-7.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16949481	Other AEs: Nephropathy... Other AEs: Nephropathy (17%) Sources: https://pubmed.ncbi.nlm.nih.gov/16949481
250 mL single, intravenous Overdose Dose: 250 mL Route: intravenous Route: single Dose: 250 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	Other AEs: Cyanosis, Bradycardia... Other AEs: Cyanosis (grade 3-5) Bradycardia (grade 3-5) Acidosis (grade 3-5) Pulmonary hemorrhage (grade 3-5) Convulsions (grade 3-5) Coma (grade 4-5) Cardiac arrest (grade 4-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf

AEs

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31718	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31718
eMolecules	36552946	https://www.emolecules.com/cgi-bin/more?vid=36552946

PubMed

Title	Date	PubMed
Evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in coronary angiography.	2007-04-17	17433962
Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency.	2007-04-17	17433961
Iodixanol vs ioxaglate for preventing contrast nephropathy: who is winner?	2007-04	17429424
Effects of iodinated contrast media on endothelium: An in vitro study.	2007-03	17113744
Contrast agent enhanced pQCT of articular cartilage.	2007-02-21	17264381
Reactive oxygen species independent cytotoxicity induced by radiocontrast agents in tubular cells (LLC-PK1 and MDCK).	2007	17365925
Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.	2006-11	17003814
Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.	2006-09-05	16949481
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.	2006-08	16611682
Effects of different contrast media on glutathione peroxidase and superoxide dismutase activities in the heart and kidneys of normal and streptozotocin-induced diabetic rats.	2006-07	16877231
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.	2006-06	16649230
The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review.	2006-04-27	16643668
Iodinated radiographic contrast media possess antioxidant properties in vitro.	2005-12	16392606
Usefulness of a new grading system based on coronary flow velocity pattern in predicting outcome in patients with acute myocardial infarction having percutaneous coronary intervention.	2005-10-01	16188518
Adverse reactions of low osmolar non-ionic and ionic contrast media when used together or separately during percutaneous coronary intervention.	2005-09	16352273
The effect of contrast media on the synovial membrane.	2005-09	16129252
N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.	2005-06	15894775
Contrast medium attenuates platelet activation and platelet-leukocyte cross-talk.	2005-05	15886810
The effects of carbon dioxide versus ioxaglate in the rat kidney.	2005-02	15713929
Ultrasound findings of iodide mumps.	2005-02	15681332
Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol.	2005-01-15	15648453
Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.	2005-01-01	15619387
Renal effects of CO2 and iodinated contrast media in patients undergoing renovascular intervention: a prospective, randomized study.	2005-01	15640411
Influence of contrast media (iopromide, ioxaglate, gadolinium-DOTA) on blood viscosity, erythrocyte morphology and platelet function.	2005	15851842
Hepatopulmonary syndrome induced by common bile duct ligation in a rabbit model: correlation between pulmonary vascular dilatation on thin-section CT and angiography and serum nitrite concentration or endothelial nitric oxide synthase (eNOS)1 expression.	2004-10-07	15467411
Similarity and difference in the acute lung injury induced by a radiographic contrast medium and an anticancer agent paclitaxel in rats.	2004-08-30	15294344
Prediction of the no-reflow phenomenon with ultrasonic tissue characterization in patients with anterior wall acute myocardial infarction.	2004-06-01	15165914
Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metanalysis.	2004-03	15139506
Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents.	2004-02	14717929
[Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography].	2003-12	15248440
No difference among modern contrast media's effect on neointimal proliferation and restenosis after coronary stenting in pigs.	2003-12	14627891
Nonionic low-osmolar contrast media have no impact on major adverse cardiac events in patients undergoing coronary stenting with appropriate antiplatelet therapy.	2003-12	14624424
Inflammatory markers increase following exposure to radiographic contrast media.	2003-09	14510756
Glaucoma as a complication of superselective ophthalmic angiography.	2003-09	13679269
Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells.	2003-08	12781870
Calcium-dependent injury of human microvascular endothelial cells induced by a variety of iodinated radiographic contrast media.	2003-06	12908704
Review article: Effects of radiographic contrast media on the lung.	2003-05	12763943
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.	2003-04	12690428
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol.	2003-03	12659083
A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.	2003-03	12642398
Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells.	2003-03	12595799
The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets.	2003-02	12871500
In vivo comparative antithrombotic effects of ioxaglate and iohexol and interaction with the platelet antiaggregant clopidogrel.	2003-01	12496519
Differential effects of the iodinated contrast agents Ioxaglate, Iohexol and Iodixanol on thrombus formation and fibrinolysis.	2003	15013276
[Arteries of the uterine cervix in reproductive age in microangiographic studies].	2002-12	12722465
[Arteries of the hilum and parenchymal part of the ovary in reproductive age in microangiographic studies].	2002-12	12722464
[Iodic allergic reaction with vasospasm occluded coronary during coronarography].	2002-12	12608133
Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells.	2002-11	12472192
Iodinated contrast media induce neutrophil apoptosis through a mitochondrial and caspase mediated pathway.	2002-11	12466250
Allergies correlated to adverse reactions induced by non-ionic monomeric and ionic dimeric contrast media for contrast enhanced CT examination.	2002-09	12520220

Patents

Sample Use Guides

In Vivo Use Guide

For PEDIATRIC ANGIOCARDIOGRAPHY the usual total dose of Hexabrix per procedure, which includes diagnostic and test doses is about 4 mL/kg. This dosage may be as small as 1.5 mL/kg and should not normally exceed 5 mL/kg. For SELECTIVE CORONARY ARTERIOGRAPHY the usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). For PHLEBOGRAPHY the dose for adults will usually range from 50-100 mL per extremity of full strength (32% iodine) Hexabrix as a single rapid injection.

Route of Administration: Intravascular

In Vitro Use Guide

Bovine patellar cartilage samples were immersed in 21 mM Hexabrix (Ioxaglic Acid) solution for 24 hours to be successfully scanned with a clinical pQCT instrument.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:48 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:48 GMT 2025`
Record UNII	HQ43CN02U9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOXAGLATE SODIUM

Official Name

English

SODIUM IOXAGLATE

Preferred Name

English

SODIUM IOXAGLATE [MART.]

Common Name

English

IOXAGLATE SODIUM [ORANGE BOOK]

Common Name

English

Sodium N-(2-hydroxyethyl)-2,4,6-triiodo-5-[2-[2,4,6-triiodo-3-(N-methylacetamido)-5-(methylcarbamoyl)benzamido]acetamido]isophthalamate

Systematic Name

English

BENZOIC ACID, 3-((((3-(ACETYLMETHYLAMINO)-2,4,6-TRIIODO-5-((METHYLAMINO)CARBONYL)BENZOYL)AMINO)ACETYL)AMINO)-5-(((2-HYDROXYETHYL)AMINO)CARBONYL)-2,4,6-TRIIODO-, SODIUM SALT

Common Name

English

Ioxaglate sodium [WHO-DD]

Common Name

English

IOXAGLATE SODIUM [USAN]

Common Name

English

HEXABRIX COMPONENT IOXAGLATE SODIUM

Common Name

English

IOXAGLATE SODIUM [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28500